<rst>
	<header>
		<relations>
			<rel name="antithesis" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="condition" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="elaboration" type="rst"/>
			<rel name="evaluation" type="rst"/>
			<rel name="evidence" type="rst"/>
			<rel name="joint" type="multinuc"/>
			<rel name="justify" type="rst"/>
			<rel name="motivation" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="restatement" type="multinuc"/>
			<rel name="restatement" type="rst"/>
			<rel name="result" type="rst"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="solutionhood" type="rst"/>
		</relations>
	</header>
	<body>
		<segment id="1" parent="2" relname="concession">Albert Bourla No, you will have to have safety of a specific population,</segment>
		<segment id="2" parent="21" relname="span">which is the standard one, but we don't have to prove the efficacy on real world data</segment>
		<segment id="3" parent="21" relname="circumstance">that will be a study that will be 30 or 40 before approval necessary.</segment>
		<segment id="4" parent="5" relname="solutionhood">Unidentified Analyst Okay, got it.</segment>
		<segment id="5" parent="22" relname="span">The other question I have is the idea of using mRNA to deliver protein or antisense sequences.</segment>
		<segment id="6" parent="23" relname="span">Where is that science? Or is this an idea of moving beyond vaccination</segment>
		<segment id="7" parent="6" relname="elaboration">and using mRNA delivery for other form of protein expression or inhibiting protein expression,</segment>
		<segment id="8" parent="9" relname="condition">where is that in terms of development?</segment>
		<segment id="9" >Albert Bourla I think it is advancing. And I think in mRNA, we're just scratching the surface right now.</segment>
		<segment id="10" parent="11" relname="elaboration">But it's not only that.</segment>
		<segment id="11" parent="24" relname="span">There are other applications, as you said,</segment>
		<segment id="12" parent="24" relname="circumstance">other vaccines but also there are other forms of mRNA that are studied.</segment>
		<segment id="13" parent="14" relname="condition">There is the [indiscernible] circular mRNA.</segment>
		<segment id="14" parent="25" relname="span">So there are a lot of technologies that they are developing.</segment>
		<segment id="15" parent="25" relname="circumstance">Unidentified Analyst How far are we from having the first non-vaccination application entering the clinic?</segment>
		<segment id="16" parent="17" relname="condition">Is this a '23, a '24, a 2030?</segment>
		<segment id="17" parent="26" relname="span">Where are we in terms of getting the science --?</segment>
		<segment id="18" parent="26" relname="evidence">Albert Bourla For cancer, there are already.</segment>
		<segment id="19" parent="20" relname="concession">So I would say that's not the vaccination.</segment>
		<segment id="20" >It is used therapeutically, right?</segment>
		<group id="21" type="span" />
		<group id="22" type="span" />
		<group id="23" type="span" parent="22" relname="result"/>
		<group id="24" type="span" />
		<group id="25" type="span" />
		<group id="26" type="span" />
	</body>
</rst>
